Clinical Trial Data with a Personalized Neoantigen Cancer Vaccine in Metastatic Colorectal Cancer
Time: 12:30 pm
day: Day One
Details:
- We have developed a heterologous prime-boost personalized neoantigen cancer vaccine using adenoviral prime and self-amp mRNA boost vectors
- Phase 1 data demonstrated good safety, immunogenicity and early signals of clinical benefit
- A randomized, controlled phase 2 trial in metastatic colorectal cancer is expected to report preliminary data from a subset of patients in 1 Q24
